The Manufacturers Life Insurance Company Acquires 22,917 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

The Manufacturers Life Insurance Company lifted its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 56.7% during the 1st quarter, HoldingsChannel reports. The fund owned 63,346 shares of the company’s stock after buying an additional 22,917 shares during the period. The Manufacturers Life Insurance Company’s holdings in Kiniksa Pharmaceuticals International were worth $3,050,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. EverSource Wealth Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth about $31,000. KBC Group NV acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth approximately $34,000. Smartleaf Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $41,000. Institutional investors own 53.95% of the company’s stock.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, Director G Bradley Cole sold 3,673 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the transaction, the director directly owned 11,672 shares in the company, valued at approximately $950,450.96. The trade was a 23.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 51.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KNSA. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. lifted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Finally, Citigroup lifted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and a consensus target price of $87.38.

Kiniksa Pharmaceuticals International Stock Down 0.6%

KNSA stock opened at $76.06 on Friday. Kiniksa Pharmaceuticals International, plc has a twelve month low of $31.78 and a twelve month high of $82.94. The company has a market cap of $5.85 billion, a P/E ratio of 78.41 and a beta of 0.05. The business’s fifty day moving average is $61.50 and its 200-day moving average is $52.41.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, hitting analysts’ consensus estimates of $0.30. The business had revenue of $243.60 million during the quarter, compared to analysts’ expectations of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. Research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.